ABSTRACT Pulmonary vascular flow resistive properties may be described by mean pulmonary arterial pressure (PAP)-cardiac output (CO) plots. The slope of the PAP-CO relationship defines the incremental resistance and the extrapolated pressure intercept defines the effective outflow pressure. We investigated effects of norepinephrine (1 1 dogs) and isoproterenol (seven dogs) on the pulmonary vascular PAP-CO relationship in a model of pulmonary hypertension produced by injection of autologous blood clots. Multiple PAP-CO coordinates were obtained with and without drug infusion. CO was varied by opening systemic arteriovenous fistulas. PAP-CO relationships were well described by a linear equation (mean r value .964 + .032). Isoproterenol increased mean CO by 61% (p < .01), and calculated pulmonary vascular resistance (PVR) decreased by 31% (p < .05), corresponding to a 35% decrease (5.1 + 2.0 to 3.3 + 0.9 mm Hg * liter min-1; p < .01) incremental resistance. In the first seven dogs to receive norepinephrine, despite a 25% increase in blood pressure (p < .01) no significant effects on CO, PAP, PVR, or PAP-CO relationship were observed. In the next four dogs, norepinephrine was infused at a lower dose to increase blood pressure 50% and a higher dose to ensure an increase in CO. In both conditions, calculated PVR fell (p < .05) compared with that before norepinephrine. However, measured incremental resistance and effective outflow pressure did not change. The discrepancy between PVR and incremental resistance seen with norepinephrine is the result of an incorrect assumption used in calculating PVR; that is, left ventricular end-diastolic pressure is the effective vascular outflow pressure in this preparation. We conclude that isoproterenol improved pulmonary hemodynamics by decreasing incremental resistance, whereas norepinephrine improved CO and increased blood pressure Several recent studies have employed an alternative approach to describe the hemodynamic properties of the pulmonary vasculature.5-14 These studies demonstrated that, over the physiologic range of blood flow and for constant outflow pressure,
MANY STUDIES have investigated the acute cardiopulmonary effects of treatment of pulmonary hypertension caused by pulmonary embolism. Both clinical1'2 and basic3 studies have documented an increase in cardiac output (CO) and a decrease in pulmonary vascular resistance (PVR) with isoproterenol, a ,3,-and 132-agonist. Other studies of canine pulmonary hypertension have reported an increase in CO and a decrease in PVR with norepinephrine.4"5 However, this change in PVR would be unexpected since norepinephrine is a mixed a-and /,3-agonist.
In these studies,1-5 PVR was calculated as mean pulmonary arterial pressure (PAP) -left ventricular filling pressure . CO. This calculation of resistance is used to reflect changes in vessel caliber and assumes that in West zone III the left ventricular filling pressure is the pulmonary vascular outflow pressure. '9 Several recent studies have employed an alternative approach to describe the hemodynamic properties of the pulmonary vasculature.5-14 These studies demonstrated that, over the physiologic range of blood flow and for constant outflow pressure, the slope of the pressure-flow relationship was constant. This slope defines the incremental resistance (pressure change per unit change in flow).`l Linear extrapolation of the pressure-flow line to zero flow defines the effective vascular outflow pressure.`I f the left ventricular filling pressure is sufficiently high, the extrapolated pressure intercept should equal that value.12 13 However, in certain conditions the extrapolated outflow pressure has been reported to exceed the apparent downstream pressure. " 1214 Accordingly, in pulmonary hypertension therapeutic interventions may affect incremental resistance and/or effective outflow pressure. Therefore the decreases in PVR with isoproterenol and norepinephrine previously reported`may be explained by decreases in one or both of these variables.
This study defines effects of isoproterenol and norepinephrine on the pulmonary pressure-flow relationship in a canine preparation of pulmonary hypertension and demonstrates that although both drugs may decrease PVR, only isoproterenol improved the pressureflow relationship.
Methods
Eighteen mongrel dogs (20 to The first seven group I dogs had PAP-CO lines generated before, during, and after infusion of norepinephrine. The pressure-flow lines were generated by manipulation of the two fistulas to obtain multiple PAP-CO coordinates. The effects of time on this preparation were determined by comparing the preinfusion lines to the postinfusion lines (see below). To determine the dose of norepinephrine, the drug was initially infused at a rate of 0.05 gg/kg/min and the rate was gradually increased until there was an approximate 25% change in blood pressure or an approximate 75% increase in CO. After a steady state was reached, the norepinephrine line was obtained during continuous drug infusion. The postinfusion line was generated approximately 20 min after the norepinephrine infusion was discontinued. By this time, measured variables had returned to values similar to those preceding drug infusion. Because there was an inhomogenous change in CO with norepinephrine in these first seven dogs, pressure-flow coordinates were obtained at two dosages of norepinephrine in an additional four dogs. The first ensured a significant increase in blood pressure and the higher dosage ensured a significant increase in CO. The preparations and measurements were identical to those described above, except that only three PAP-CO coordinates were obtained at each dosage. To determine the doses of norepinephrine, the drug was initially infused at a rate of 0.05 ug/kg/min and the rate was gradually increased until blood pressure increased approximately 50%; the infusion was then stabilized at this rate (NE,). After measurements were made, the norepinephrine infusion was increased until CO increased approximately 100% (NE2).
The seven group II dogs (receiving isoproterenol) underwent a modification of the above protocol. After the 1 hr stabilization period following embolization, either a control pressure-flow line or a pressure-flow line during infusion of isoproterenol was generated. The sequence was altered to control for the effects of time.
To determine the dose of isoproterenol, the drug was initially infused at a rate of 0.2 gg/kg/min and the rate was gradually increased until there was an approximate 75% increase in CO, a 20% decrease in blood pressure, or a 20% increase in heart rate. After a steady state was reached, the isoproterenol line was obtained during continuous infusion.
In the four dogs in which the isoproterenol line was obtained first, the postembolization line was then generated approximately 20 min after the isoproterenol infusion was discontinued. By this time measured variables had returned to values similar to those preceding drug infusion.
To determine the effects of embolization and the two drug infusions on gas exchange variables, samples of arterial and mixed venous blood were obtained in each experimental condition for subsequent analysis. Analysis of arterial and venous blood gases was performed on a Corning 165/2 plt Blood Gas Analyzer.
Hemodynamic To assess hemodynamic effects of emboli, norepinephrine, and isoproterenol, a two-way analysis of variance was performed. If a significant F value was obtained, Tukey's test was carried out to determine which means differed.
To obtain values for slope and extrapolated pressure intercept, pressure-flow coordinates were analyzed by linear regression analysis (least-squares method) and were considered to fit a linear relationship at a significance level of p < .05. CO was considered to be the independent variable and PAP the dependent variable. For the group of dogs given norepinephrine, an analysis of variance and Tukey's test was used to test for differences in slopes and intercepts of the pressure-flow relationships. In the seven dogs treated with isoproterenol, effects of the drug on slopes and intercepts were assessed with the paired t test.
Results
The mean hemodynamic effects of embolization and infusion of norepinephrine in the first seven dogs are illustrated in table 1. Despite a significant decrease in CO, emboli markedly increased PAP and PVR.
Norepinephrine increased mean blood pressure by 25% (p < .01). There was a tendency for CO and PAP to increase and for PVR to decrease, but these changes did not achieve statistical significance. Note that LVEDP did not change with norepinephrine. The data for the next four dogs, which received the two levels of norepinephrine infusion, are presented in table 2. In this group, NE1 increased blood pressure approximately 50% (p < .05). As in the first group of dogs, although NE1 tended to increase CO and PAP, these changes were not significant. However, a significant decrease in PVR was noted (p < .05). During NE2 there was a significant increase in PAP and CO (both p < .05) compared with preinfusion values and PVR was 37% lower than the preinfusion value (p < .05). Mean hemodynamic values (± SD) with fistula closed (n = 7). HR = heart rate; BP = blood pressure; other abbreviations as in text.
Ap < .01; Bp < .001 (both compared with previous condition). Mean hemodynamic values (± SD) with fistula closed (n = 4). Abbreviations as in table 1.
Ap < .05 compared with before norepinephrine.
As depicted in table 3, isoproterenol had a marked effect on pulmonary hemodynamics. CO increased 63% (p < .05) and blood pressure decreased 14% (p < .05). PAP remained constant and PVR decreased 31% (p < .05).
For each condition in each dog, linear regression analysis was performed on the PAP-CO coordinates and the values for slope, intercept, and linear regression coefficient (r) are listed in tables 4, 5, and 6. In each condition the LVEDP varied by 1 mm Hg or less during generation of the PAP-CO lines. Note the high r values in each dog in each experimental condition. Accordingly, we are confident that over the range of pressures and flows tested, our data are well described by a linear equation.
As illustrated in table 4, the mean value of slope and intercept were unchanged before, during, and after infusion of norepinephrine in the first seven dogs. Table 5 depicts the values for the four dogs given two doses of norepinephrine and demonstrates that the value for slope and intercept were not significantly affected by either infusion rate. Figure 1 plots the PAP-CO coordinates for conditions before, during, and after norepinephrine. Note that all coordinates appear to fall on the same linear relationship. Similarly, figure 2 plots the PAP-CO coordinates in the four dogs that received the two doses of norepinephrine. In each dog all coordinates appear to fall approximately on the same relationship.
As shown in Mean hemodynamic value (± SD) with fistula closed (n = 7).
Ap < .05; Bp < .01; Cp < .001 (all compared with previous condition). Table 7 illustrates that neither embolization nor treatment affected Pao2 or intrapulmonary shunt.
Discussion
We used the pulmonary vascular PAP-CO relationship to investigate pulmonary hemodynamic effects of norepinephrine and isoproterenol in a canine preparation of pulmonary hypertension. Despite marked systemic effects, norepinephrine did not alter the pul- flow pressure. Several studies have confirmed that under certain conditions the effective outflow pressure may exceed left ventricular filling pressure in zone 112 1`a nd alveolar pressure in zone II 80, 12, 14 In the current study, all pressure-flow relationships were well described by a linear equation; therefore we used the slopes and extrapolated intercepts to define incremental resistance and to estimate effective outflow pressure.
Although this study was not designed to investigate effects of emboli on pressure-flow characteristics, a recent study demonstrated that the predominant effect of multiple emboli was to markedly increase effective outflow pressure. 3 In this preparation of pulmonary hypertension, at a given dose both norepinephrine and isoproterenol increased CO and decreased calculated PVR, suggesting corresponding changes in vascular surface area and incremental resistance.
On the other hand, indicates that norepinephrine did not significantly affect the pulmonary vascular pressure-flow relationship. The apparent discrepancy between the decrease in calculated PVR with norepinephrine and the lack of change in incremental resistance with the drug is explained by the assumption made in the calculated value that the LVEDP equals the effective pulmonary vascular downstream or outflow pressure. However, the pressure intercept of the pressure-flow plots was always much higher than the LVEDP. Recent work in the same canine preparation of pulmonary hypertension demonstrated that changes in the left atrial pressure in this condition had absent to trivial effects on the upstream pressure (i.e., PAP) when CO was held constant.`This work verified that in this condition the left ventricular filling pressure does not represent the effective downstream pressure. Similarly, in a recent study, investigators used an isolated lung to investigate pulmonary vascular effects of hypoxia. 6 Hypoxia In a recent study we investigated effects of hydralazine on pulmonary pressure-flow characteristics in the same canine preparation of pulmonary hypertension. 13 Hydralazine had a marked pulmonary hemodynamic effect: CO doubled and PAP remained constant. In this instance the improvement in pulmonary hemodynamics was predominantly explained by a decrease in outflow pressure, not by a change in incremental resistance. Mean outflow pressure decreased from 29 to 23 mm Hg with hydralazine. Considered together, these results indicate that the clinical effects of vasoactive drugs may improve pulmonary hemodynamics via two mechanisms, decreasing incremental resistance and outflow pressure. These concepts could be applied in treating pulmonary hypertension, in which simultaneous use of two vasoactive drugs might be additive in decreasing right ventricular afterload.
Although numerous studies have assessed shortterm pulmonary hemodynamic effects of norepinephrine and isoproterenol, the current study is the first to investigate effects of these agents on pulmonary pressure-flow characteristics. Although both drugs decreased PVR, only isoproterenol improved pressureflow characteristics.
